Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer (NCT07288177)
A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants With Non-Small Cell Lung Cancer
🩺 Plain-English Summary (8th-Grade Level)
This Phase 2 study will be conducted in different countries around the world with up to about 240 participants. The purpose of this study is to evaluate how well Rina-S works against lung cancer. The treatment in this study is Rina-S monotherapy (by itself). All participants will receive active drug; no one will be given placebo. The treatment duration will be different for every participant, but an average of 12 months is expected. Participants will be asked to attend 1 to 5 visits at the study clinic for each cycle (duration of cycle is 3 weeks). If a participant's cancer stays the same or gets better, and there are not any serious problems, participants can keep getting study treatment for as long as the study is open. Participation in the study will require visits to the study site(s). During site visits, there will be various tests (such as blood draws) and procedures (such as recording of heart activity, imaging/X-rays) to monitor whether the study treatment is safe and effective.
Who can join: Review the eligibility criteria below.
Location: Compassionate Cancer Care Center — Fountain Valley, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (74 Sites)
Showing the first 25 of 74 sites.
- Compassionate Cancer Care Center — Fountain Valley, California
- Kaiser Permanente San Diego Mission Road — San Diego, California
- Providence Medical Foundation (St. Joseph Heritage Healthcare) — Santa Rosa, California
- MedStar Georgetown University Hospital — Washington D.C., District of Columbia
- Moffitt Cancer Center and Research Institute — Tampa, Florida
- Emory Winship Cancer Institute — Atlanta, Georgia
- St. Vincent Frontier Cancer Center — Billings, Montana
- Nebraska Hematology-Oncology — Lincoln, Nebraska
- Astera Cancer Care — East Brunswick, New Jersey
- ONE Onc: New York Oncology Hematology — Albany, New York
- Montefiore Medical Park — The Bronx, New York
- UNC Health - University of North Carolina — Chapel Hill, North Carolina
- Williamette Valley Cancer Institute and Research Center — Eugene, Oregon
- Providence Portland Medical Center — Portland, Oregon
- Providence Oncology & Hematology Care Clinic - Westside — West Haven-Sylvan, Oregon
- Tennessee Oncology - Nashville St. Thomas Midtown Clinic — Nashville, Tennessee
- Tennessee Oncology Nashville - SCRI Oncology Partners — Nashville, Tennessee
- Baylor Charles A. Sammons Cancer Center — Dallas, Texas
- Virginia Cancer Specialists — Fairfax, Virginia
- St Andrews Medical Centre — Adelaide,
- Chris O'Brien Lifehouse — Camperdown,
- Icon Cancer Centre Hobart — Hobart,
- Icon Cancer Care - Townsville — Hyde Park,
- St John of God Murdoch Hospital — Murdoch,
- GenesisCare North Shore — Saint Leonards,
📞 Contact the Study Coordinator
Phone: (457) 020-2728
Email: clinicaltrials@genmab.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Non-small Cell Lung Cancer (NSCLC)
- Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Oakland, California
- HER3-DXd (Patritumab Deruxtecan; U3-1402) in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer — Santa Monica, California
- PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung — Tampa, Florida
- U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer — Duarte, California
- Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC — Duarte, California
- Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE) — Birmingham, Alabama
Explore by condition: All Non-small Cell Lung Cancer (NSCLC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.